Key Takeaways
- Novo Nordisk (NVO) announced that its next-generation obesity drug, CagriSema, failed to meet the primary endpoint of non-inferiority in weight loss compared to Eli Lilly’s (LLY) Tirzepatide.
- In the REDEFINE 4 trial, patients on CagriSema achieved a 23.0% weight reduction over 84 weeks, falling short of the 25.5% reduction seen with Tirzepatide.
- Shares of Novo Nordisk plummeted 11% following the news, while Eli Lilly shares rose approximately 4% in early trading, reinforcing Lilly's market leadership.
- The trial results represent a significant strategic setback for Novo Nordisk as it seeks to challenge the clinical dominance of Lilly’s Zepbound and Mounjaro.
- Despite the miss, Novo Nordisk noted that CagriSema maintained a safe and well-tolerated profile, with plans to explore higher-dose combinations in future studies.
Novo Nordisk (NVO) reported disappointing headline results today from its REDEFINE 4 Phase 3 trial, a high-stakes head-to-head study comparing its experimental combination therapy, CagriSema, against Eli Lilly’s (LLY) Tirzepatide. The trial failed to demonstrate that CagriSema was at least as effective as Tirzepatide, a blow to Novo's efforts to reclaim the top spot in the global obesity market.
The 84-week open-label trial involved 809 participants with obesity and at least one comorbidity. Data showed that patients adhering to the treatment regimen on CagriSema (2.4 mg/2.4 mg) lost 23.0% of their body weight, compared to 25.5% for those on the maximum 15 mg dose of Tirzepatide. When accounting for all participants regardless of adherence, the gap remained, with CagriSema achieving 20.2% weight loss versus 23.6% for Tirzepatide.
Market reaction was swift and severe for the Danish drugmaker, with Novo Nordisk (NVO) shares dropping 11% in European and U.S. trading. Investors had widely viewed CagriSema as Novo's best chance to leapfrog the efficacy of Eli Lilly’s dual-agonist platform. Conversely, Eli Lilly (LLY) saw its stock climb 4%, as the data suggests Tirzepatide remains the "gold standard" for weight loss efficacy among currently available and late-stage injectables.
The failure to meet the non-inferiority margin is particularly stinging given that CagriSema—a combination of the GLP-1 semaglutide and the amylin analogue cagrilintide—was designed specifically to provide additive weight-loss benefits. While CagriSema did outperform Novo’s own Wegovy in previous trials, it has consistently struggled to hit the 25% weight loss threshold that analysts believe is necessary to unseat Tirzepatide.
Despite the primary endpoint miss, Novo Nordisk executives emphasized the drug's safety profile and the substantial weight loss achieved in absolute terms. Martin Holst Lange, Novo’s head of R&D, stated that the company remains encouraged by the 23% reduction and is already moving forward with the REDEFINE 11 trial. This new study will investigate higher-dose combinations and personalized dosing schedules to see if CagriSema's efficacy ceiling can be raised.
The competitive landscape for metabolic health continues to intensify as Roche (ROG) and other players release positive early-stage data. Analysts suggest that Novo Nordisk may now face increased pressure to accelerate its oral GLP-1 programs or pursue aggressive M&A to bolster its pipeline against Eli Lilly's widening lead. For now, the REDEFINE 4 results confirm that the "weight loss war" remains firmly in Lilly's favor on the basis of pure efficacy.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.